• Imatinib (STI571) Experimental Workflow Guide

  2026-09-07

  Translate Imatinib target inhibition into reproducible kinase, proliferation, and erythroleukemia assays with concentration, exposure, and readout choices grounded in mechanism. The workflow also shows how the compound can test Abl-linked effects alongside the HIF-α/GATA1 biology highlighted in recent K562 research.

• BMX-IN-1: From Kinase Probe to Lysosome Biology

  2026-09-05

  BMX-IN-1 is a selective, irreversible BMX kinase inhibitor for dissecting cancer signaling and host–pathogen biology. This article explains how recent mechanistic evidence connects BMX activity with ATP6V1E1 phosphorylation, lysosomal acidification, and Mycobacterium tuberculosis survival.

• (Z)-4-Hydroxytamoxifen in Reliable Assays

  2026-09-04

  This scenario-driven guide explains how (Z)-4-Hydroxytamoxifen (SKU B5421) can improve experimental control in estrogen-receptor assays, from solvent handling to interpretation of viability and proliferation data. It connects practical assay design with breast cancer relapse research while distinguishing documented product properties from workflow recommendations.

• PHF2 Drives Neuroinflammation in Alzheimer’s Disease

  2026-09-04

  A 2025 Molecular Psychiatry study identifies the histone demethylase PHF2/KDM7C as an upstream regulator of inflammatory gene expression in Alzheimer’s disease. By combining human tissue, patient-derived neurons, genomic profiling, and 5xFAD experiments, the authors connect PHF2 reduction with lower glial activation, improved glutamatergic synaptic function, and better spatial memory.

• CircRHOBTB3, NONO, and MAOA in Prostate Cancer

  2026-09-03

  A 2025 Cancer Letters study identifies circRHOBTB3 as a downregulated tumor-suppressive circular RNA in prostate cancer and defines a circRNA–NONO–MAOA pathway controlling proliferation and metastasis. Its combination of metastatic-model sequencing, RNA localization, protein-interaction, transcriptional, and functional assays provides a useful framework for studying RNA-mediated regulation in advanced prostate cancer.

• EDI3 Inhibition in HER2-Resistant Breast Cancer

  2026-09-03

  Keller et al. identify the glycerophosphodiesterase EDI3/GPCPD1 as a metabolic vulnerability in ER-HER2-positive breast cancer, particularly after resistance to HER2-targeted treatment. Their combination of patient-tissue analysis, pathway perturbation, cell studies, and xenograft experiments supports EDI3 inhibition as a strategy for reducing viability and tumor growth, while also defining important limits for translation.

• Lactate, GPR81, and Insulin-Independent Glucose Uptake

  2026-09-02

  A 2026 Cell Research study identifies lactate as an insulin-independent regulator of skeletal-muscle glucose uptake and defines a GPR81–FARP1–RAC1–GLUT4 mechanism linking exercise metabolism to glucose control. Its genetic, pharmacological, metabolic, and human-association evidence suggests that GPR81 may complement insulin signaling, while also highlighting important boundaries for translating the pathway into therapeutic research.

• Recombinant Human IL-15 in Neuroimmune Assays

  2026-09-02

  Recombinant Human IL-15 provides a controlled immune perturbation for T-cell and NK-cell experiments. This article connects IL-15 assay design with new findings on early-life adversity, oxytocin signaling, and innate defensive behavior while defining the limits of that cross-domain interpretation.

• Perospirone (SM-9018 Free Base) Research Workflows

  2026-09-01

  Build receptor-centered schizophrenia research assays while accounting for a newly characterized vascular Kv1.5-related off-target effect. This practical guide shows how to prepare Perospirone, separate receptor pharmacology from ion-channel activity, and troubleshoot concentration, solvent, and electrophysiology variables.

• 4μ8C: Precision Control of ER Stress Signaling

  2026-09-01

  4μ8C is a selective IRE1α RNase tool for separating ER stress sensing from downstream signaling. This thought-leadership guide connects its use in hypoxia and cancer research with broader lessons in proteostasis, experimental validation, and translational decision-making.

• Dynasore for Endocytosis Research

  2026-08-31

  Dynasore enables reversible, dose-dependent disruption of dynamin-dependent membrane scission for mechanistic studies of nanoparticle uptake, receptor trafficking, and synaptic vesicle recycling. This workflow-centered guide shows how to pair a dynamin GTPase inhibitor with viability controls and pathway-aware interpretation, particularly in human corneal epithelial cell assays.

• Baricitinib for JAK1/2 and PSC Assays

  2026-08-31

  Baricitinib (LY3009104) converts spatially observed IL-6 activity into a testable JAK1/2 perturbation workflow. This guide covers dose finding, phospho-STAT3 readouts, epithelial–immune co-culture design, and troubleshooting for PSC, inflammatory signaling, and preclinical arthritis studies.

• Triamcinolone: Protocol and QC Guidance

  2026-08-30

  Triamcinolone (SKU B1859) provides a defined synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. It is a research-use reagent only; its water and ethanol insolubility, DMSO handling requirements, and limited solution-storage stability must be considered during assay design.

• Telmisartan Workflow for Cardiac Hypertrophy

  2026-08-29

  Use Telmisartan as an AT1-receptor-centered control in angiotensin II cardiac hypertrophy models, then compare upstream receptor blockade with downstream RIP3/CaMKII interventions. This workflow combines solvent-aware handling, dose-range design, orthogonal phenotyping, and troubleshooting for reproducible cardiovascular disease research.

• S63845 and the Context of MCL1-Driven Apoptosis

  2026-08-28

  S63845 is a selective MCL1 inhibitor that converts anti-apoptotic dependency into a measurable mitochondrial death response. This thought-leadership perspective connects its mechanism to ferroptosis–apoptosis crosstalk and provides translational guidance for model selection, assay design, combination studies, and preclinical interpretation.

8350 records 2/557 page Previous Next 12345 下5页 Last page